MDGL MADRIGAL PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1157601 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY92.8%
TTM net income YoY46.2%
TTM EPS YoY24.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-10.7%
Net margin-10.9%
FCF margin-11.8%
EBITDA margin-10.6%
Returns
ROE-24.8%
ROA-11.1%
ROIC (approx.)-21.6%
Asset turnover1.02x
Leverage & solvency
Liabilities / assets56.3%
Debt / equity0.54x
Current ratio3.05x
Interest coverage-4.75x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.1%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $958.40M | $180.13M | $0 | $0 | $0 |
| Cost of revenue | — | $6.23M | $0 | $0 | — |
| Gross profit | — | $173.90M | $0 | $0 | — |
| R&D expense | $388.52M | $236.72M | $272.35M | $245.44M | $205.16M |
| SG&A expense | $813.83M | $435.06M | $108.15M | $48.13M | $37.32M |
| Operating income | -$300.10M | -$497.88M | -$380.50M | -$293.57M | -$242.48M |
| Interest expense | $22.31M | $14.67M | $12.71M | $3.96M | $0 |
| Pretax income | -$158.50M | -$465.90M | -$373.60M | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$288.28M | -$465.89M | -$373.63M | -$295.35M | -$241.85M |
| EBITDA | -$298.59M | -$496.78M | -$379.97M | -$293.10M | -$242.08M |
| EPS (basic) | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 |
| EPS (diluted) | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 |
| Weighted avg. shares (diluted) | 22.43M | 21.27M | 18.69M | 17.14M | 16.54M |
| Balance sheet | |||||
| Cash & equivalents | $198.69M | $105.02M | $99.92M | $331.55M | $36.27M |
| Short-term investments | $784.87M | $826.23M | $534.22M | $27.23M | $234.08M |
| Receivables | $134.48M | $53.82M | $0 | — | — |
| Inventory | $74.84M | $34.07M | $0 | — | — |
| Current assets | $1.25B | $1.03B | $637.28M | $361.37M | $271.68M |
| PP&E, net | $1.50M | $2.19M | $1.55M | $601,000 | $851,000 |
| Intangibles | $7.38M | $4.73M | $0 | — | — |
| Total assets | $1.26B | $1.04B | $640.55M | $362.57M | $273.33M |
| Current liabilities | $310.29M | $169.28M | $118.55M | $115.89M | $76.84M |
| Long-term debt | $339.88M | $117.57M | $115.48M | $49.29M | $0 |
| Total debt | $339.88M | $117.57M | $115.48M | $49.29M | $0 |
| Total liabilities | $656.90M | $287.86M | $235.21M | $165.18M | $77.22M |
| Shareholders' equity | $602.69M | $754.38M | $405.33M | $197.39M | $196.11M |
| Net debt | $141.19M | $12.55M | $15.56M | -$282.26M | -$36.27M |
| Shares outstanding | 22.84M | 22.00M | 19.88M | 18.10M | 17.10M |
| Cash flow statement | |||||
| Operating cash flow | -$189.55M | -$455.57M | -$324.23M | -$224.86M | -$183.92M |
| Capital expenditure | $467,000 | $1.46M | $1.48M | $217,000 | $209,000 |
| Free cash flow | -$190.02M | -$457.03M | -$325.71M | -$225.07M | -$184.13M |
| Investing cash flow | $32.32M | -$274.39M | -$502.52M | $206.69M | -$5.05M |
| Financing cash flow | $255.98M | $735.06M | $595.12M | $313.45M | $171.24M |
| Depreciation & amortization | $1.51M | $1.10M | $527,000 | $467,000 | $405,000 |
| Stock-based compensation | $98.13M | $79.88M | $49.73M | $31.62M | $26.87M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.